ClinicalTrials.gg
CompletedNCT05667740Updated Sep 5, 2024

Safety, Tolerability and Immunogenicity of an Inactivated Whole-cell Pneumococcal Vaccine Gamma-PN3.

A Phase 1 interventional study of Gamma-PN3 and Prevenar-13 in Pneumococcal Infections, sponsored by GPN Vaccines. Completed at 1 site in Australia. Open to participants aged 50 Years to 69 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-05.

Sponsored by GPN Vaccines · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
118
Allocation
Randomized
Ages
50 Years to 69 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Pneumococcal Infections with a site in Australia — 3 open to participants now, 3 under way, 1 of them phase 3. Pneumococcal Infections · Australia.

Enrollment
13th of 16
118 · median 851
Started
2023
with 2 others
Phase 1
3 of 16
2 open now
Registered
11th of 16
by date
Lead sponsor
3 of 16
GPN Vaccines

Among the 16 studies in Pneumococcal Infections with a site in Australia, this one is the 13th largest by enrollment, is one of 3 that started in 2023, is one of 3 in phase 1, and was the 11th registered.

Pneumococcal Infections

299 studies on the registry are indexed under Pneumococcal Infections; 26 are open to participants now.

Browse Pneumococcal Infections studies →

Open to participants now

3 of the 16 studies in Pneumococcal Infections with a site in Australia are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.

This study: 50 Years to 69 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Pneumococcal Infections with a site in Australia, or all of them as a file.
02

Study summary

This is a randomised placebo-controlled first-in-man dose-ranging study to determine safety and markers of efficacy.

Read the detailed description

The study is of double-blind; parallel groups dose escalation design. In each cohort of 39 participants 30 will receive Gamma-PN3; 3 will receive Prevenar; 3 will receive Pneumovax and 3 saline placebo.

The doses of Gamma-PN3 will be 50mcg; 250 mcg and 1000 mcg of protein content.

03

Conditions studied

  • Pneumococcal Infections
04

Who can participate

Ages eligible
50 Years to 69 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female volunteers aged 50 to 69 years inclusive at Screening.
  2. In good health as determined by the outcome of medical history, physical examination, and clinical judgement by the Investigator. Chronic stable non-inflammatory conditions such as hypertension, hyperlipidemia, well-controlled type 2 diabetes, stable asthma, controlled psychiatric conditions such as anxiety or depression, stable ischemic heart disease without heart failure are permitted, as determined by the Investigator.
  3. Willing and able to give voluntary written before screening assessments commence.
  4. Vital signs within the following ranges (inclusive):

    • Body temperature 35.5 to 37.7°C
    • Heart rate 50 to 100 beats per minute
    • Respiratory rate 12 to 22 breaths per minute
    • Systolic blood pressure 90 to 160 mmHg
    • Diastolic blood pressure 50 to 95 mmHg
  5. 12-lead (ECG) parameters within the following ranges:

    • \& QTcF - males ≤450 msec. females ≤470 msec
    • PR 100 to 240 msec inclusive
    • HR 50 to 100 bpm inclusive
  6. Willing and able to communicate with the Investigator and study team and understands the requirements of the study.
  7. Willing and able to undertake the study visits and all assessments, including possessing a suitable device and access to the internet for using the web-based electronic diary (e.g., smartphone, tablet, or computer) and able to use the device for this purpose.
  8. Vaccinated against severe acute respiratory syndrome corona virus 2 (SARS-CoV-2; COVID-19) as per State Health advice at the time of recruitment.

Exclusion criteria

Exclusion Criteria:

  1. History of a previous Pneumovax 23® vaccination.
  2. History of a previous Prevenar 13® vaccination.
  3. Splenectomy or cochlear implant, due to likelihood of having received pneumococcal vaccination at age less than 70 years.
  4. Positive serology blood test for (HIV) antibodies, virus (HBV) surface antigen or virus (HCV) antibodies.
  5. Infectious disease including but not limited to COVID-19 and influenza within 30 days before Screening and any time between Screening and Day 1 first dose, as this may confound immune response to study vaccine.
  6. Liver function tests (including [AST], alanine aminotransferase [ALT], ) >1.5 (ULN).
  7. abnormalities in laboratory tests (biochemistry, haematology, coagulation, urinalysis), physical examination, 12-lead or vital signs during the Screening period that, in the opinion of the Investigator, would affect immune response to vaccination and/or ability to fully participate in the study and/or not be in the individual's best interest to participate in the study. One retest per abnormality is permitted.
  8. Participation in another clinical study of any or licensed product (including investigational COVID-19 vaccines, drugs, medical devices) or medical procedure within 4 weeks from last study visit before screening.
  9. Plan to have a vaccine during the study period including COVID-19 booster.
  10. Have had a within three months of the first dose of study product or any other vaccine (including any COVID-19 vaccine) within 28 days of the first dose of study product. Examples of live vaccines include, but are not limited to the following: measles, mumps, rubella, chicken pox/zoster, monkeypox, yellow fever, rabies, Bacillus Calmette-Guérin, and typhoid (oral) vaccines. Seasonal influenza vaccines for injection are generally killed virus vaccines and are permitted if administered at least 28 days before the first dose of study treatment and not during the enrollment or the study period. However, intranasal influenza vaccines are live attenuated vaccines and are not permitted within three months of first dose.
  11. Have received blood or blood-derived products in the last three months before screening, which might interfere with assessment of the immune response.
  12. Known or suspected congenital or acquired immunodeficiency; or receipt of therapy such as anti-cancer chemotherapy or radiation therapy within the last six months before screening; or long-term systemic therapy (prednisone or equivalent for more than two consecutive weeks within the last month before screening, depot or intraarticular steroids within 3 months before screening).
  13. A systemic inflammatory condition such as rheumatoid arthritis or inflammatory bowel disease.
  14. History of severe allergic reaction e.g., severe cutaneous adverse reaction or anaphylaxis to any medicinal product or to any of the study products, including .
  15. Current alcohol abuse (> 21 U/week for men and 14 U/week for women), substance dependence including nicotine/tobacco smoking (defined as more than 5 cigarettes or tobacco/nicotine equivalent per day; smoking or vaping will not be permitted while at the study unit), any use of illicit drugs or other addiction which might interfere with the ability to comply with study procedures in the opinion of the Investigator, positive drugs of abuse screen (tricyclic antidepressants are not exclusionary if consistent with medical history) or positive alcohol breath test at Screening or pre-dose. One re-test permitted for drugs of abuse screen where justified (e.g., false positive suspected).
  16. Clinically significant chronic illness that, in the opinion of the Investigator, is at a stage where it might interfere with study conduct or completion. Examples include congestive heart failure, COAD with breathlessness interfering with daily activities; psychiatric conditions, poorly controlled asthma, or diabetes
  17. Any chronic medical condition e.g., asthma, gout, which is likely to need systemic corticosteroid therapy during the study. -
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
118 participants (actual)

Study arms

  • Experimental
    Gamma-PN3

    Inactivated whole-cell pneumococcal vaccine at 50, 250 or 1000 mcg of protein content. One dose on Day 1 and second dose Day 29

    Biological: Gamma-PN3

  • Placebo comparator
    Placebo

    Saline on Day 1 and second dose Day 29

    Drug: Placebo

  • Active comparator
    Prevenar-13

    Licensed pneumococcal vaccine on Day 1 and saline on Day 29

    Biological: Prevenar-13

  • Active comparator
    Pneumovax-23

    Licensed pneumococcal vaccine on Day 1 and saline on Day 29

    Biological: Pneumovax-23

Interventions

06

What researchers measure

Primary outcomes

  1. Adverse events and clinical laboratory measures

    Safety

    Time frame: 57 days

  2. Immunogenicity

    Frequency of participants with \> 4 fold increase in IgG titre at 29 and 57 days.

    Time frame: 57 days

Secondary outcomes

  1. OPKA response

    Opsonophagocytic antibodies effective against different serotypes of Streptococcus pneumoniae will be assessed at Days 29 and 57

    Time frame: 57 days

07

Study locations

1 site
  • CMAX
    Adelaide, South Australia 5000, Australia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2023 to primary completion in Oct 2023, 8 months.

Of 27 phase 1 interventional studies under Pneumococcal Infections, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 16. This study's 8 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2022
First posted
Dec 29, 2022
StartActual
Jan 16, 2023
Primary completionActual
Oct 8, 2023
CompletionActual
Oct 8, 2023
Last update
Sep 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05667740
Lead sponsor
GPN Vaccines
Responsible party
Sponsor
First posted
Dec 29, 2022
Start date
Jan 16, 2023
Primary completion
Oct 8, 2023
Completion
Oct 8, 2023
Last update
Sep 5, 2024

Study contacts

Sepehr Shakib, MD
principal investigator · CMAX

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion